Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

BWV - Blue Water Vaccines, Inc. Stock Price, Fair Value and News

$0.16-39.54 (-99.60%)
Delayed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

BWV Price Action

BWV RSI Chart

JunJulAugSepOctNovDec2024Feb0102030405060708090

BWV Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

-39.86

Price/Sales (Trailing)

1.3K

EV/EBITDA

-39.93

Price/Free Cashflow

-318.54

BWV Price/Sales (Trailing)

2025FebMarAprMayJunJul2004006008001K1.2K1.4K

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BWV Fundamentals

BWV Revenue

Revenue (TTM)

1.3M

Rev. Growth (Yr)

-84.89%

Rev. Growth (Qtr)

4.79%

2024AprJulOct2025Apr1.4M1.6M1.8M2M2.2M2.4M2.6M

BWV Earnings

Earnings (TTM)

-44.2M

Earnings Growth (Yr)

83.42%

Earnings Growth (Qtr)

72.24%

20212022202320242025-60M-50M-40M-30M-20M-10M0

BWV Profitability

Operating Margin

66.45%

EBT Margin

-3403.15%

Return on Equity

-747.65%

Return on Assets

-231.1%

Free Cashflow Yield

-0.31%

BWV Investor Care

Shares Dilution (1Y)

98.67%

Diluted EPS (TTM)

0.28

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
2025FebMarAprMayJun1.4M1.6M1.8M2M2.2M2.4M2.6M
Net sales
YearQ1Q2Q3Q4
20251.9M1.3M00
20240002.5M
20230000
Get all data in R, Python etc through our Historical Stock Data APIs

About Blue Water Vaccines, Inc.

Blue Water Biotech, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Vaccines, Inc. and changed its name to Blue Water Biotech, Inc. in April 2023. Blue Water Biotech, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
 WEBSITEbwbioinc.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES12

Blue Water Vaccines, Inc. Frequently Asked Questions

What is the ticker symbol for Blue Water Vaccines, Inc.? What does BWV stand for in stocks?

BWV is the stock ticker symbol of Blue Water Vaccines, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Blue Water Vaccines, Inc. (BWV)?

As of Thu Jul 31 2025, market cap of Blue Water Vaccines, Inc. is 1.76 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BWV stock?

You can check BWV's fair value in chart for subscribers.

Is Blue Water Vaccines, Inc. a good stock to buy?

The fair value guage provides a quick view whether BWV is over valued or under valued. Whether Blue Water Vaccines, Inc. is cheap or expensive depends on the assumptions which impact Blue Water Vaccines, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BWV.

What is Blue Water Vaccines, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 31 2025, BWV's PE ratio (Price to Earnings) is -39.86 and Price to Sales (PS) ratio is 1.33 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BWV PE ratio will change depending on the future growth rate expectations of investors.